BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

959 related articles for article (PubMed ID: 26976796)

  • 1. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
    Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
    Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
    Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
    Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coffee Bioactive
    Quarta S; Scoditti E; Carluccio MA; Calabriso N; Santarpino G; Damiano F; Siculella L; Wabitsch M; Verri T; Favari C; Del Rio D; Mena P; De Caterina R; Massaro M
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
    Tsuchida A; Yamauchi T; Takekawa S; Hada Y; Ito Y; Maki T; Kadowaki T
    Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
    Boujon V; Uhlemann R; Wegner S; Wright MB; Laufs U; Endres M; Kronenberg G; Gertz K
    J Mol Med (Berl); 2019 Aug; 97(8):1127-1138. PubMed ID: 31147725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
    Dietz M; Mohr P; Kuhn B; Maerki HP; Hartman P; Ruf A; Benz J; Grether U; Wright MB
    ChemMedChem; 2012 Jun; 7(6):1101-11. PubMed ID: 22489042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
    Lecka-Czernik B
    IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.
    Hu X; Feng Y; Liu X; Zhao XF; Yu JH; Yang YS; Sydow-Bäckman M; Hörling J; Zierath JR; Leng Y
    Diabetologia; 2007 May; 50(5):1048-57. PubMed ID: 17333104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
    Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
    Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
    Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
    Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
    PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary human adipocytes.
    Chuang CC; Martinez K; Xie G; Kennedy A; Bumrungpert A; Overman A; Jia W; McIntosh MK
    Am J Clin Nutr; 2010 Dec; 92(6):1511-21. PubMed ID: 20943792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dietary Isoflavone Daidzein Reduces Expression of Pro-Inflammatory Genes through PPARα/γ and JNK Pathways in Adipocyte and Macrophage Co-Cultures.
    Sakamoto Y; Kanatsu J; Toh M; Naka A; Kondo K; Iida K
    PLoS One; 2016; 11(2):e0149676. PubMed ID: 26901838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
    Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
    PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic Acid and hydroxytyrosol in human adipocytes.
    Scoditti E; Massaro M; Carluccio MA; Pellegrino M; Wabitsch M; Calabriso N; Storelli C; De Caterina R
    PLoS One; 2015; 10(6):e0128218. PubMed ID: 26030149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.